Heymann Dominique, Ory Benjamin, Gouin François, Green Jonathan R, Rédini Françoise
Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives. Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes 1, France.
Trends Mol Med. 2004 Jul;10(7):337-43. doi: 10.1016/j.molmed.2004.05.007.
Bisphosphonates (BPs) have been used successfully for many years to reduce the skeletal complications associated with the benign and malignant bone diseases that are characterized by enhanced osteoclastic bone resorption. Until recently, it was thought that the clinical efficacy of BPs in the treatment of cancer patients with bone metastases was purely a result of the inhibition of osteoclast-mediated bone resorption. However, recent studies have demonstrated that BPs inhibit the growth, attachment and invasion of cancer cells in culture and promote their apoptosis. These results suggest that BPs are also anti-cancer agents, raising the possibility that BPs could inhibit cancer-cell colonization in visceral organs. However, results from clinical trials are conflicting, and whether BPs possess anti-cancer effects or not remains controversial.
双膦酸盐（BPs）已成功应用多年，用于减少与以破骨细胞介导的骨吸收增强为特征的良性和恶性骨疾病相关的骨骼并发症。直到最近，人们还认为BPs在治疗骨转移癌患者中的临床疗效完全是抑制破骨细胞介导的骨吸收的结果。然而，最近的研究表明，BPs在体外可抑制癌细胞的生长、黏附和侵袭，并促进其凋亡。这些结果表明，BPs也是抗癌剂，这增加了BPs可能抑制癌细胞在内脏器官中定植的可能性。然而，临床试验的结果相互矛盾，BPs是否具有抗癌作用仍存在争议。
Zotero 插件